Background The RAID score is a relatively new patient-derived composite score assessing seven important domains of the impact of rheumatoid arthritis (RA). It is unknown how the RAID score correlates with various disease measures among patients with early RA.
Objectives To examine associations between the RAID score and other patient reported outcome measures (PROMs) and clinical, laboratory and ultrasonographic disease measures in an inception cohort of DMARD naïve patients with early RA.
Methods Patients from 11 centers who fulfilled the 2010 ACR/EULAR classification criteria for RA were included between 2010 and 2013. All patients had symptom duration (from first swollen joint) <2 years and were DMARD naïve with indication for DMARD treatment. Patients were stratified according to level of RAID score at baseline, and a RAID score of ≤3 was considered low, >3-6 moderate and >6 high. Disease measures were compared across RAID level groups using either Kruskal-Wallis or ANOVA, and we assessed the correlation between RAID and other measures using Pearson or Spearman correlation coefficients, as appropriate.
Results A total of 229 patients were included, 61.1% female, 81.2% ACPA-positive and with mean (SD) age 51.0 (13.6) years. At baseline, mean (SD) RAID score was 4.5 (0.7). There were statistically significant differences in all disease measures across low, moderate and high RAID score groups, except for the power Doppler ultrasonography score (table). Correlation analyses revealed statistically significant correlations between RAID score and all other measures. Correlations between RAID and Patient global and EQ-5D, respectively, were strong (r≥0.70), whereas the correlations between RAID and Ritchie, DAS, Physician global and SF-36 Physical and Mental Components Summary measures were moderate (r ≥0.4-0.7). The remaining correlations were weak (r<0.4).
Conclusions The RAID score was associated with both patient-reported and objective disease measures in this inception cohort of DMARD naïve RA patients. These findings support the validity of RAID in patients with early RA.
Disclosure of Interest L. Nordberg: None declared, E. Lie: None declared, A.-B. Aga: None declared, M. Maehlen: None declared, I. Olsen: None declared, T. Uhlig: None declared, S. Lillegraven: None declared, T. Kvien: None declared, E. Haavardsholm Grant/research support from: Abbvie, Pfizer, MSD, Roche, UCB.